DR-523 Precise and Cost-Effective Identification of Homologous Recombination Deficiency
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-523 Precise and Cost-Effective Identification of Homologous Recombination Deficiency
Patients whose cancer cells have defective DNA repair, known as the homologous recombination deficiency (HRD) phenotype, benefit from treatment with …
DR-522 Understand mechanism of resistance in HR deficient cancers
Patients with homologous recombination deficiency (HRD), a condition when cancer cells cannot effectively repair DNA double-strand breaks. HRD tumours, especially …
DR-485 Mapping MSK-IMPACT genetic insights to large scale genomic and transcriptomic events in breast cancer
Molecular alterations occurring at the genomic level represent the mainstay process promoting breast cancer development. In this context, at Memorial …
DR-511 The biological and clinical consequences of structural variants across tumor types
Cancers are characterized by substantial genomic instability, including large genomic alterations known as structural variants (SVs), which remain relatively underexplored. …
DR-514 Sex-Specific Genomic Differences in Early-Onset and Average-Onset Esophagogastric Adenocarcinoma: An Integrated Whole-Genome Study
This project studies whether younger patients with esophageal or gastric adenocarcinoma have different genetic tumour characteristics than older patients, and …
DR-498 Interoperable Multi-Modal Data Platform for AI-Driven Precision Medicine Biomarker Discovery at the Future Medicines Institute
Biomedical data are often poorly standardised and fragmented across formats, limiting integration and slowing the discovery of biomarkers that can …
DR-490 Detection of DNA damage response (DDR) dysfunction from tumor sequencing data
To continue unchecked growth, cancer cells bypass mechanisms that protect our genomic code, such as DNA repair and telomere maintenance. …
DR-482 Decoding the role of complex genomic rearrangements in driving metastasis, cancer genome evolution and drug resistance
Over the last years, my laboratory has revealed that cancer genomes are riddled by complex forms of structural variants (SVs), …
DR-500 Somatic mutagenesis in cancer: characterization, models and methods for driver detection
This project aims to generate new knowledge about mutational processes in tumors and to develop improved computational methodology for finding …
DR-487 Pan-cancer landscapes of transcriptional and genomic heterogeneity in metastatic tumors
Metastasis, the spread of cancer from its original site to other organs, is the leading cause of cancer-related deaths. This …
DR-489 Adapting the DeepTumour Algorithm to Plasma Whole Genome Sequencing
The major factor predicting a human cancer’s behaviour is its organ of origin. However, roughly 3% of the time a …
DR-509 Clinical utility and genomic predictors of treatment (non-)response in metastatic colorectal cancer
Metastatic colorectal cancer is treated with chemotherapy and targeted drugs. Although recent studies have identified genes that may predict how …
De kennis die we met WGS vergaren kan ons een stap dichterbij ons doel brengen om voor elke patiënt een effectieve en passende behandeling te vinden, niet op basis van ‘one size fits all’, maar aangepast aan de kenmerken van de patiënt en de tumor.